The effects of methanolic extract of clinacanthus nutans L. (belalai gajah) on atherogenic risk markers in a type 2 diabetic rat model by Azemi, Ahmad Khusairi
THE EFFECTS OF METHANOLIC EXTRACT OF 
Clinacanthus nutans L. (BELALAI GAJAH) ON 
ATHEROGENIC RISK MARKERS IN A TYPE 2 













UNIVERSITI SAINS MALAYSIA 
 
2021 
THE EFFECTS OF METHANOLIC EXTRACT OF 
Clinacanthus nutans L. (BELALAI GAJAH) ON 
ATHEROGENIC RISK MARKERS IN A TYPE 2 











Thesis submitted in fulfillment of the requirements 
for the degree of 







Alhamdulillah, praise to Allah S.W.T. His blessings had helped me in 
completing this thesis. First and foremost, I would like to express a special 
appreciation and thanks to my supervisor, Professor Dr. Aida Hanum Ghulam Rasool 
who have been very helpful and supportive of me. Her advices, critical comments, 
and valuable insights have guided me throughout this PhD project and thesis 
completion. I also would like to thank my co-supervisor, Dr. Siti Safiah Mokhtar for 
her guidance and valuable advices and guidance. I would like to acknowledge 
Universiti Sains Malaysia for the Short term grant (304.PPSP.6315096) and Bridging 
grant (304.PPSP.6316127) which had provided financial support for this project. In 
addition, special thanks to Universiti Sains Malaysia (USM) for granting me a 
fellowship under the Graduate Assistant (GA) scheme. I also would like to thank all 
my laboratory mates (Wee Chee Lee, Seetha Munisamy, Sagir Mustapha, and Dr. 
Che Ismail), staffs from Pharmacology Department & Laboratory, Central Research 
Laboratory (CRL) and Animal Research and Service Centre (ARASC) that had 
helped me a lot in the laboratory work. Last but not least, I would like to express my 
deepest gratitude to my family for their endless love and prayers. They have always 
been very supportive and encouraging in whatever I do, including for this PhD 
project. As a sign of appreciation, I dedicate this thesis to them and hope that I have 









TABLE OF CONTENTS iii 
LIST OF TABLES xiii 
LIST OF FIGURES xv 
LIST OF ABBREVIATIONS xviii 
LIST OF SYMBOLS xxiii 
ABSTRAK xxv 
ABSTRACT xxviii 
CHAPTER 1 INTRODUCTION 1 
1.1 Background of the Study 1 
1.2 Study Rationale 6 
1.3  Hypothesis of the Study 9 
1.4 Objectives of the Study 10 
CHAPTER 2 LITERATURE REVIEW 10 
2.1 Vasculature 10 
 2.1.1 Structure and Function of the Blood Vessel Wall 10 
 2.1.2 Endothelium  11 
 2.1.3 Nitric oxide 12 
  2.1.3 (a) Synthesis of NO 13 
  2.1.3 (b) Pathways of NO 14 
2.2 Diabetes Mellitus 17 
	 iv 
 2.2.1 Definition and Classification 17 
 2.2.2 Diagnosis, Symptoms and Medication 18 
 2.2.3 Animal Model of Diabetes Mellitus 20 
2.3 Diabetes and Vascular Complications 20 
 2.3.1 Effect of Diabetes on Endothelium 22 
  2.3.1 (a) Endothelium-dependent Relaxation 23 
  2.3.1 (b) Endothelium-dependent Contraction 23 
 2.3.2 Effect of Diabetes on Vascular Smooth Muscle 24 
  2.3.2 (a) Vascular Smooth Muscle Relaxation 24 
  2.3.2 (b) Vascular Smooth Muscle Contraction 24 
2.4 Atherosclerosis 25 
 2.4.1 Oxidative Stress and Atherosclerosis Development in Diabetes 27 
  2.4.1 (a) Vascular Oxidative Stress Markers 28 
   2.4.1 (a)(i) Superoxide Dismutase (SOD) 28 
   2.4.1 (a)(ii) Lipid Peroxidation Products 29 
 2.4.2 Inflammation and Atherosclerosis Development in Diabetes 31 
  2.4.2 (a) Vascular Inflammatory Cytokine TNF-a 32 
2.5 Clinacanthus nutans 33 
 2.5.1 Geographical Distribution and Botanic Description 33 
 2.5.2 Traditional Practices 35 
 2.5.3 Scientific Findings 35 
 2.5.4 Phytochemistry 36 
 2.5.5 Pharmacological Properties of C. nutans that are Potentially 39 
	 v 
Useful for Preventing or Ameliorating Diabetic Vasculopathy 
CHAPTER 3 METHODOLOGY 49 
3.1 A Comparative Study on Endothelial Function, Metabolic Profile, 
Oxidative Stress, Inflammation, and Aortic Intima-media Thickness 
Status in Control and Type 2 Diabetic (T2DM) Rats 
49 
 3.1.1 Animals 49 
  3.1.1 (a) Sample Size Calculation 49 
  3.1.1 (b) Ethical Approval 50 
  3.1.1 (c) Animal Handling 50 
  3.1.1 (d) Experimental Design 51 
  3.1.1 (e) High-fat Diet Preparation 51 
  3.1.1 (f) Induction of Diabetes 52 
  3.1.1 (g) The Measurement of FBG Concentration and Body 
Weight 
52 
  3.1.1 (h) Blood Sample, Serum Preparation and Lipid 
Profile Analysis and Atherogenic Index 
53 
  3.1.1 (i) Dissection and Isolation of Thoracic Aorta 54 
 3.1.2 Functional Study 54 
  3.1.2 (a) Materials 54 
   3.1.2 (a)(i) Organ Bath 54 
   3.1.2 (a)(ii) Physiological Saline Solution (PSS) 56 
   3.1.2 (a)(iii) Pharmacological Agents for 
Vascular Functional Responses 
58 
	 vi 
  3.1.2 (b) Methodology 60 
   3.1.2 (b)(i) Preparation and Mounting of the 
Arteries 
60 
   3.1.2 (b)(ii) Smooth Muscle Viability Test 62 
   3.1.2 (b)(iii) Endothelial Function Test 63 
   3.1.2 (b)(iv) Vascular Response Study 64 
   3.1.2 (b)(v) Functional Study Parameters 65 
 3.1.3 Tissue Lysate Preparation 68 
 3.1.4 Total Protein Quantification in the Tissue Lysate 68 
 3.1.5 Western Blotting 72 
  3.1.5 (a) Materials 72 
   3.1.5 (a)(i) Solutions 74 
   3.1.5 (a)(ii) Tissue Lysate Preparation 76 
   3.1.5 (a)(iii) Preparation of Gels for SDS-PAGE 76 
   3.1.5 (a)(iv) Sample Preparation 77 
  3.1.5 (b) Methodology 77 
   3.1.5 (b)(i) SDS-Polyacrylamide Gel 
Electrophoresis (-PAGE) 
77 
   3.1.5 (b)(ii) Transfer of Protein from Gels to the 
PVDF Membrane 
78 
   3.1.5 (b)(iii) Blocking and Antibodies Incubation 78 
   3.1.5 (b)(iv) Visualization of Protein Expression 79 
 3.1.6 Measurement of Aortic Tissue Oxidative Stress Markers 79 
	 vii 
  3.1.6 (a) Malondialdehyde Levels 79 
   3.1.6 (a)(i) Materials 79 
   3.1.6 (a)(ii) Methodology 80 
  3.1.6 (b) Superoxide Dismutase Activity 81 
   3.1.6 (b)(i) Materials 81 
   3.1.6 (b)(ii) Methodology 83 
 3.1.7 Measurement of Aortic Tissue Inflammation Marker, TNF-a 
Levels 
84 
  3.1.7 (a) Materials 84 
  3.1.7 (b) Methodology 86 
 3.1.8 Histopathology 88 
  3.1.8 (a) Materials 88 
  3.1.8 (b) Methodology 90 
 3.1.9 Statistical Analysis and Data Presentation 92 
3.2 Clinacanthus nutans 93 
 3.2.1 Collection of Plant Material and Plant Species Identification 93 
 3.2.2 Preparation of Crude Methanolic Leaves Extract 93 
 3.2.3 Phytochemical Screening of CNME 94 
  3.2.3 (a) Test for Alkaloid 94 
  3.2.3 (b) Test for Saponins 94 
  3.2.3 (c) Test for Flavonoids 94 
  3.2.3 (d) Test for Tannins 95 
  3.2.3 (e) Test for Triterpenes and Phytosterols 95 
	 viii 
 3.2.4 Gas Chromatography-Mass Spectrophotometry (GC-MS) 
Analysis 
95 
3.3 Effect of Clinacanthus nutans of Endothelial Function, Metabolic 
Profile, Oxidative Stress, Inflammation, and Aortic Intima-media 
Thickness in Non-diabetic and T2DM Rats 
96 
 3.3.1 Animals and Experimental Design 96 
 3.3.2 Functional Study 98 
 3.3.3 Total Protein Quantification 98 
 3.3.4 Western Blotting 98 
 3.3.5 Oxidative Stress Analysis 99 
  3.3.5 (a) Malondialdehyde Levels 99 
  3.3.5 (b) Superoxide Dismutase Activity 99 
 3.3.6 TNF-a levels 99 
 3.3.7 Histopathology 99 
 3.3.8 Statistical Analysis and Data Presentation 99 
CHAPTER 4 RESULTS 101 
4.1 A Comparative Study on Endothelial Function, Metabolic Profile, 
Oxidative Stress, Inflammation, and Aortic Intima-media Thickness 
in Non-diabetic and T2DM Rats 
101 
 4.1.1 General Characteristic 101 
 4.1.2 Serum Lipid Profile and Atherogenic Index 101 
 4.1.3 Functional Study 102 
  4.1.3 (a) Relaxation in Aorta of Non-Diabetic and Diabetic 102 
	 ix 
Rats 
  4.1.3 (b) Contraction in Aorta of Non-Diabetic and Diabetic 
Rats 
104 
 4.1.4 Western Blottting 107 
 4.1.5 Oxidative Stress Biomakers Levels 108 
  4.1.5 (a) MDA Levels 108 
  4.1.5 (b) SOD Activity 108 
 4.1.6 TNF-a Levels 109 
 4.1.7 Histopathological Changes in the Thoracic Aorta of Non-
diabetic and Diabetic Rats 
110 
  4.1.7 (a) Histopathological Evaluation 110 
  4.1.7 (b) Intima-media Thickness 111 
4.2 Clinacanthus nutans 112 
 4.2.1 Percentage Yield of CNME 112 
 4.2.2 Phytochemical Constituents of CNME 112 
 4.2.3 GC-MS Profile of CNME 113 
4.3 Effect of Clinacanthus nutans of Endothelial Function, Metabolic 
Profile, Oxidative Stress, Inflammation, and Aortic Intima-Media 
Thickness Status in Control and Type 2 Diabetic Rats 
116 
 4.3.1 General Characteristic of Study Rats 116 
 4.3.2 Serum Lipid Profile and Atherogenic Index 118 
 4.3.3 Functional Study 119 
  4.3.3 (a) Relaxation in Aorta of Non-diabetic and Diabetic 119 
	 x 
Rats 
  4.3.3 (b) Contraction in Aorta of Non-diabetic and Diabetic 
Rats 
122 
 4.3.4 Western Blotting 124 
 4.3.5 Oxidative Stress Markers Levels 125 
  4.3.5 (a) MDA Levels 125 
  4.3.5 (b) SOD Activity 127 
 4.3.6 TNF-a Levels 128 
 4.3.7 Histopathological Changes in the Thoracic Aorta of Non-
diabetic and Diabetic Rats 
129 
  4.3.7 (a) Histological Findings 129 
  4.3.7 (b) Intima-media Thickness 132 
CHAPTER 5 DISCUSSION 134 
5.1 Summary of Results 134 
5.2 Comparative Study on Atherogenic Risk Markers in Non-diabetic and 
T2DM Model 
135 
 5.2.1 Body Weight 136 
 5.2.2 Fasting Blood Glucose (FBG) 137 
 5.2.3 Serum Lipid Profile and Atherogenic Index 137 
 5.2.4 Aortic Tissue Oxidative Stress Markers 139 
 5.2.5 Aortic Tissue Inflammation Marker 143 
 5.2.6 Aortic Relaxation in Non-diabetic and T2DM Rat Model 144 
  5.2.6 (a) Endothelium-dependent Relaxation 144 
	 xi 
  5.2.6 (b) Endothelium-independent Relaxation 147 
 5.2.7 Aortic Contraction in Non-diabetic and T2DM Rat Model 147 
  5.2.7 (a) Endothelium-dependent Contraction 147 
  5.2.7 (b) Endothelium-independent Contraction 149 
 5.2.8 Histopathological Evaluation and IMT of Aorta 151 
5.3 Clincanthus nutans 152 
 5.3.1 Phytochemical Screening of C. nutans Methanolic Leaves 
Extract (CNME) 
152 
 5.3.2 GC-MS Analysis of CNME 155 
5.4 Effect of CNME in Non-diabetic and T2DM Rat Model 156 
 5.4.1 Effect of CNME on Body Weight 156 
 5.4.2 Effect of CNME on FBG Concentration 157 
 5.4.3 Effect of CNME on Lipid Profile and Atherogenic Index 159 
 5.4.4 Effect of CNME on Oxidative Stress Markers Levels 161 
 5.4.5 Effect of CNME on Aortic Tissue Inflammation  163 
 5.4.6 Effect of CNME on Relaxation in Aorta of Non-diabetic and 
T2DM Rat Model 
165 
  5.4.6 (a) Endothelium-dependent Relaxation 165 
  5.4.6 (b) Endothelium-independent Relaxation 167 
 5.4.7 Effect of CNME on Contraction in Aorta of Non-diabetic and 
T2DM Rat Model 
168 
  5.4.7 (a) Endothelium-dependent Contraction  168 
  5.4.7 (b) Endothelium-independent Contraction 169 
	 xii 
 5.4.8 Histopathological Evaluation and IMT of Aorta 171 
    
CHAPTER 6 CONCLUSION 173 
6.1 Summary 173 
6.2 Significance and Novelty of the PhD Study 174 
6.3 Study Limitation and Recommendations 176 
REFERENCES 177 
APPENDICES  
APPENDIX A: ANIMAL ETHICS APPROVAL  
APPENDIX B: PLANT SPECIES IDENTIFICATION REPORT  
APPENDIX C: PUBLISHED PAPERS AND PRESENTED ABSTRACT  












LIST OF TABLES 
 
  Page 
 




Table 2.2 Phenolic compounds identified from C. nutans. 
 
37 
Table 2.3 Hypoglycemic effects of C. nutans. 
 
42 
Table 2.4 Antioxidant effects of C. nutans. 
 
44 
Table 2.5 Anti-inflammatory effects of C. nutans. 
 
46 
Table 2.6 Hypolipidemic effects of C. nutans. 
 
48 





Table 3.2 List of instruments used in functional study. 
 
55 
Table 3.3 List of chemicals used in PSS preparation. 
 
57 
Table 3.4 Characteristic of the drugs used in functional study. 
 
60 
Table 3.5 List of instruments used in Western blotting. 
 
72 
Table 3.6 List of antibodies used in Western blotting. 
 
72 
Table 3.7 List of chemicals and consumables used in Western blotting. 
 
73 
Table 3.8 Formula of resolving and stacking gel preparation. 
 
75 
Table 3.9 SOD standard preparation. 
 
82 
Table 3.10 List of the materials used to measure TNF-a.  
 
85 
Table 3.11 List of instruments used in histopathology study. 
 
88 




Table 4.1 Body weight, FBG, serum lipid profile levels and atherogenic 




















Table 4.5 Body weight and FBG changes in non-diabetic and high-fat 





























LIST OF FIGURES 
 
 
  Page 
Figure 2.1 Anatomy of the blood vessel.  
 
11 
Figure 2.2 The synthesis of the nitric oxide. 
 
14 
Figure 2.3 Schematic diagram of possible mechanism of NO-




Figure 2.4 Pathophysiology of atherosclerosis in diabetes. 
 
26 
Figure 2.5 (A) C. nutans plant (B) C. nutans leaves 
 
34 
Figure 3.1 Experimental design in non-diabetic and diabetic rats. 
 
51 
Figure 3.2 Setup of the organ bath system. 
 
55 
Figure 3.3 Automatic isolated organ bath. 
 
56 
Figure 3.4 Mounting of the aorta in organ bath chamber.  
 
62 
Figure 3.5 Diagrammatical illustrations of organ bath tracing and 






Figure 3.6 Diagrammatical illustrations of organ bath tracing and 






Figure 3.7 Sample plate format. 
 
70 
Figure 3.8 Serial dilution of the standard.  
 
86 
Figure 3.9 Experimental design of the effect of CNME in non-




Figure 4.1 Concentration response curves to ACh (10-9 - 10-4 M). 
 
103 
Figure 4.2 Concentration response curves to sodium nitroprusside 




Figure 4.3 Concentration response curves to calcium ionophore (10-9 









Figure 4.5 (A) Representative Western blots showing the expression 
of eNOS in thoracic aorta of non-diabetic and diabetic 
groups. (B) Graphical representation of the data, 






Figure 4.6 MDA levels in aorta of non-diabetic and diabetic groups. 
 
108 
Figure 4.7 SOD activity in aorta of non-diabetic and diabetic groups. 
 
109 





Figure 4.9 Representative histopathological changes in the thoracic 






Figure 4.10 IMT of thoracic aorta in non-diabetic and diabetic groups. 
 
112 





Figure 4.12 Concentration response curves to ACh (10-9 to 10-4 M). 
 
120 
Figure 4.13 Concentration response curves to sodium nitroprusside 




Figure 4.14 Concentration response curves to calcium ionophore (10-9 









Figure 4.16 Representative Western blots showing the expression of 
eNOS protein in thoracic aorta of C, C+CNME, DM, 
DM+Met and DM+CNME groups. (B) Graphical 






Figure 4.17 MDA levels of thoracic aorta in non-diabetic and diabetic 




Figure 4.18 SOD activity of thoracic aorta in non-diabetic and 





Figure 4.19 TNF-a levels of thoracic aorta in non-diabetic and 




Figure 4.20 Effect of CNME on histopathological changes in the rats’ 






Figure 4.21 IMT of thoracic aorta in non-diabetic and diabetic rats 
























ACh Acetylcholine  
AGEs Advanced glycation end products 
AI Atherogenic index 
AMPK 5’ AMP-activated protein kinase 
ANOVA Analysis of variance 
BHT Butylated hydroxytoluene 
BSA Bovine serum albumin 
Ca2+ Calcium 
cGMP Cyclic guanosine monophosphate 
CNME Clinacanthus nutans methanolic leaves extract 
COX Cyclooxygenase 
CyPA Cyclophilin A 
DAG Diacylglycerol 
DM Diabetes mellitus 
DPPH 2,2-diphenyl-1-picrylhydrazyl 
ECM Extracellular matrix 
ED Endothelial dysfunction 
EDCF Endothelium-derived contracting factor 
EDRF Endothelium-derived relaxing factor 
ELISA Enzyme-linked immunosorbent assay 
	 xix 
eNOS Endothelial nitric oxide synthase 
ER Endoplasmic reticulum 
FAD Flavin adenine dinucleotide 
FBG Fasting blood glucose 
FMN Flavin mononucleotide 
FRIM Forest Research Institute Malaysia 
GC-MS Gas chromatography- mass spectrometry 
GLUT2 Glucose transporter 2 
GPx Glutathione peroxidase 
GSH Glutathione 
GTP Guanosine triphosphate 
HBA1C Glycated hemoglobin 
HCl Hydrochloric  
HDL-C High-density lipoprotein 
HRP Horseradish peroxidase 
IACUC Institutional of Animal Care and Use Committee 
IDF International Diabetes Federation 
IgG Immunoglobulins G 
IL Interleukins 
IMT Intima-media thickness 
iNOS Inducible nitric oxide synthase 
IP3 Inositol 1,4,5-triphosphate  
IP3R Inositol 1,4,5-triphosphate receptor 
	 xx 
KCl Potassium chloride 
L-NAME L-nitro-arginine methyl ester 
LDL-C Low-density lipoprotein 
LPS Lipopolysaccharide 
MCP-1 Monocytes chemoattractant protein-1 
MDA Malondialdehyde 
MLC Myosin light-chain 
MLCK Myosin light-chain kinase 
MLCP Myosin light-chain phosphatase 
mRNA Messenger ribonucleic acid 
NADPH Nicotinamide adenine dinucleotide phosphate 
NF-kb Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHMS National Health and Morbidity Survey 
NIST National Institute Standard and Technology 
nNOS Neuronal nitric oxide synthase 
NO Nitric oxide 
NOS Nitric oxide synthase 
oxLDL-C Oxidized low-density lipoprotein cholesterol 
PKC Protein kinase C 
PKG Protein kinase G 
PSS Physiological saline solution 
PUFAs Polyunsaturated fatty acids 
PVDF Polyvinylidene difluoride 
	 xxi 
RIPA Radioimmunoprecipitation assay 
ROS Reactive oxygen species 
SD Standard deviation 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM Standard error of mean 
SERCA Sarcoplasmic/endoplasmic reticulum calcium ATPase 
sGC Soluble guanylyl cyclase 
SOD Superoxide dismutase 
STZ Streptozotocin 
T1DM  Type 1 diabetes mellitus 
T2DM Type 2 diabetes mellitus 
TBA Thiobarbituric acid 
TBARS Thiobarbituric acid reactive substances 
TBS Tris Buffer Saline 
TBST Tris Buffer Saline/Tween-20 
TC Total cholesterol 
TG Triglycerides 
TLR Toll-like receptor 
TNF-a Tumor necrosis factor-alpha 
TxA2 Tromboxane A2 
USM Universiti Sains Malaysia 
VCAM Vascular cell adhesion molecule 
VDCC Voltage dependent calcium channel 
	 xxii 
VSMC Vascular smooth muscle cell 






















°C Degree celsius 
g Gamma 
± Plus-minus 
< Less than 

















































KESAN EKSTRAK METANOL Clinacanthus nutans L. (BELALAI GAJAH) 
PADA PENANDA RISIKO ATEROGENIK DALAM MODEL TIKUS 




Diabetes mellitus dikaitkan dengan disfungsi endotelium (ED); ia 
menyebabkan kerosakan progresif vaskular. Clinacanthus nutans telah 
didokumentasikan mempunyai sifat antioksida, hipoglisemik, hipolipidemik dan 
anti-radang; sifat-sifat ini berpotensi meningkatkan fungsi endotelium dan mencegah 
perkembangan aterosklerosis. Pertama, kajian ini bertujuan untuk menilai fungsi 
endotelium, perubahan struktur awal vaskular, tekanan oksidatif dan keradangan 
vaskular pada model tikus diabetes jenis 2 (T2DM) yang disebabkan oleh diet tinggi 
lemak (HFD) dan streptozotocin (STZ) dos rendah (STZ). Kedua, untuk mengetahui 
kesan ekstrak methanol daun C. nutans (CNME) pada parameter dan model yang 
sama. Bahagian pertama kajian: Tikus Sprague-Dawley jantan dibahagikan kepada 
kumpulan bukan diabetes dan diabetes (n = 12 setiap kumpulan). Kumpulan diabetes 
diberi HFD selama 4 minggu sebelum suntikan intraperitoneal STZ; dan dikorbankan 
pada minggu 15. Tahap glukosa darah puasa (FBG) dan profil lipid diukur sebelum 
pengorbanan tikus. Setelah dikorbankan, aorta diasingkan; pengenduran dan 
pengecutan berperantara- dan tidak berperantara-endotelium aorta toraks ditentukan 
menggunakan organ bath. Ekspresi enzim eNOS aorta dinilai melalui pemblotan 
Western. Superoxide dismutase (SOD), malondialdehyde (MDA), factor nekrosis 
	 xxvi 
tumor factor-alpha (TNF-α) aorta, perubahan histopatologi dan ketebalan intima-
media aorta (IMT) juga diukur. Bahagian kedua kajian: Tikus Sprague-Dawley 
jantan dibahagikan kepada kumpulan bukan diabetes dan diabetes; diabetes teraruh 
oleh pemakanan HFD dan STZ dos rendah. Selepas tujuh minggu teraruh diabetes, 
tikus dibahagikan kepada lima kumpulan (n = 12 setiap kumpulan): kawalan bukan 
diabetes (C), bukan diabetes yang dirawat dengan CNME selama 4 minggu (500 
mg/kg/hari) (C+CNME), tikus diabetes yang tidak dirawat (DM), diabetes yang 
dirawat dengan metformin (300 mg/kg/hari)(DM+Met) dan diabetes yang dirawat 
dengan CNME (500 mg/kg/hari) (DM+CNME). Tikus dikorbankan setelah 4 minggu 
rawatan dan parameter eksperimen serupa dengan bahagian 1 kajian diambil. Hasil; 
Bahagian pertama: Tikus diabetes mempunyai FBG, jumlah kolesterol (TC), 
trigliserida (TG), kolesterol lipoprotein berketumpatan rendah (LDL-C) dan indeks 
aterogenik (AI) yang lebih tinggi berbanding tikus bukan diabetes. Pengenduran 
berperantara-endotelium menurun, sementara pengecutan berperantara- dan tidak 
berperantara-endothelium meningkat pada tikus diabetes. Ekspresi eNOS lebih 
rendah pada tikus diabetes. Tahap IMT, MDA dan TNF- α meningkat sementara 
aktiviti SOD lebih rendah pada tikus diabetes berbanding dengan tikus bukan 
diabetes. Bahagian kedua: Kedua-dua kumpulan DM+CNME dan DM+Met telah 
mengurangkan tahap FBG berbanding kumpulan DM. Rawatan dengan CNME dan 
metformin pada tikus diabetes menunjukkan TC, TG, LDL-C dan AI yang lebih 
rendah berbanding dengan tikus diabetes yang tidak dirawat. Kedua-dua kumpulan 
diabetes yang dirawat dengan CNME dan metformin meningkatkan pemulihan 
kerosakan vasopengenduran berperantara-endotelium; ini dikaitkan dengan 
	 xxvii 
peningkatan ekspresi protein eNOS aorta. Rawatan dengan CNME dan metformin 
juga mengurangkan pengecutan berperantara dan tidak berperantara-endotelium 
aorta pada tikus diabetes. Tahap IMT, MDA dan TNF-α dalam aorta dikurangkan 
sementara aktiviti SOD lebih tinggi dalam kedua-dua rawatan CMNE dan metformin 
pada tikus diabetes. Hasil kajian ini menunjukkan bahawa model T2DM yang teraruh 
oleh HFD dan STZ dos rendah mempunyai ED yang berkaitan dengan perubahan 
awal struktur vaskular, dan peningkatan tekanan oksidatif dan keradangan vaskular. 
Rawatan dengan ekstrak C. nutans meningkatkan vasopengenduran berperantara-
endotelium, pengurangan pengecutan berperantara- dan tidak berperantara-
endotelium, peningkatan ekspresi eNOS dan SOD, tahap AI, MDA, TNF-α yang 
lebih rendah, dan pengurangan IMT pada aorta tikus T2DM; semua kesan ini 
setanding dengan tikus diabetes yang dirawat metformin. Oleh itu, ekstrak metanol 
daun C. nutans berpotensi untuk diterokai lebih lanjut sebagai tambahan dalam 
rawatan T2DM untuk mencegah atau mengurangkan keparahan diabetes yang 









THE EFFECTS OF METHANOLIC EXTRACT OF Clinacanthus nutans L. 
(BELALAI GAJAH) ON ATHEROGENIC RISK MARKERS IN A TYPE 2 




Diabetes mellitus is associated with endothelial dysfunction (ED); causing 
progressive vascular damage. Clinacanthus nutans has been documented to have 
antioxidant, hypoglycemic, hypolipidemic and anti-inflammatory properties; 
properties with the potential to improve endothelial function and prevent 
atherosclerosis development. Firstly, this study aims to evaluate endothelial function, 
early vascular structural changes, vascular oxidative stress and inflammation in a 
model of type 2 diabetes (T2DM) rat induced by high-fat diet (HFD) and low-dose 
streptozotocin (STZ). Secondly, to determine the effects of C. nutans methanolic 
leaves extract (CNME) on the above parameters on the same model. First part of 
study: Male Sprague-Dawley rats were divided into non-diabetic and diabetic groups 
(n=12 per group). Diabetic groups were fed 4 weeks of HFD before intraperitoneal 
injection of STZ; and sacrificed at week 15. Fasting blood glucose (FBG) and lipid 
profile were measured prior to sacrifice. Upon sacrifice, the aorta was isolated; 
endothelial-dependent and -independent relaxations and contractions were 
determined using the organ bath. Aortic endothelial nitric oxide synthase (eNOS) 
expression was assessed via Western blotting. Aortic superoxide dismutase (SOD), 
malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-a), histopathological 
	 xxix 
changes and aortic intima-media thickness (IMT) were also measured. Second part 
of study: Male Sprague-Dawley rats were divided into non-diabetic and diabetic 
groups. After seven week of diabetes induction, rats were divided into five groups 
(n=12 per group): non-diabetic control (C), non-diabetic treated with 4 weeks of 
CNME (500 mg/kg/daily)(C+CNME), untreated diabetic rats (DM), diabetic treated 
with metformin (300 mg/kg/daily)(DM+Met) and diabetic treated with CNME (500 
mg/kg/daily)(DM+CNME). Rats were sacrificed after 4 weeks of treatment and 
experimental parameters similar to part 1 of study were performed. Results; First 
part: Diabetic rats have higher FBG, total cholesterol (TC), triglycerides (TG), low-
density lipoprotein cholesterol (LDL-C) and atherogenic index (AI) compared to 
non-diabetic rats. Endothelium-dependent relaxation was decreased while 
endothelial-dependent and -independent contractions were increased in diabetic rats. 
eNOS expression was lower in diabetic rats. IMT, MDA and TNF-a levels were 
increased while SOD activity lower in diabetic rats. Second part: Both DM+CNME 
and DM+Met groups reduced FBG levels compared to the DM group. Treatment 
with CNME and metformin in diabetic rats showed lower TC, TG, LDL-C and AI 
compared to untreated diabetic rats. Both diabetic-treated with CNME and 
metformin groups significantly improved the impairment in endothelium-dependent 
vasorelaxation; this was associated with increased expression of eNOS. Treatment 
with CNME and metformin also reduced endothelium-dependent and -independent 
contractions in diabetics. Aortic IMT, MDA and TNF-α levels were reduced while 
SOD activity was higher in both CMNE and metformin treated diabetic rats. These 
results demonstrated that the T2DM model induced by HFD and low-dose STZ has 
	 xxx 
ED associated with early vascular structural changes, and increased vascular 
oxidative stress and inflammation. Treatment with C. nutans extract improved 
endothelial-dependent vasodilatation, reduced endothelial-dependent and -
independent contractions, increased eNOS expression and SOD levels, lower AI, 
MDA, TNF-a levels, and reduced IMT in aorta of T2DM rats; all these effects were 
comparable with metformin-treated diabetic rats. Thus, the methanolic extract of C. 
nutans leaves has the potential to be further explored as an adjunct in the treatment 








1.1. Background of the Study 
Diabetes mellitus is a metabolic disorder characterized by altered glucose and 
lipid metabolism, resulting in persistent hyperglycemia. It is a known risk factor for 
atherosclerosis and cardiovascular diseases (Tabit et al., 2010). The prevalence of 
diabetes mellitus has increased globally in recent years. According to the 
International Diabetes Federation, there are about 463 million adults living with 
diabetes mellitus, accounting for about 9.3% of the global population. This figure is 
predicted to rise to 528 million by the year 2030 and 700 million by the year 2045 
(IDF, 2019). There is an alarming increase in the prevalence of diabetes mellitus in 
Malaysia, as reported by the National Health and Morbidity Survey (NHMS). Also, 
based on the NHMS 2019 report, there are about 3.9 million diabetic patients in 
Malaysia, which accounts for about 18.3% of the Malaysian population. This was an 
increase compared to the findings of 2011 and 2015 of 11.2% and 13.4% 
respectively (Ministry of Health Malaysia, 2019).  
The chronic nature of diabetes mellitus requires long-term monitoring to 
minimize related secondary complications. Hence, the management of diabetes 
mellitus constitutes an ever-increasing proportion of global as well as Malaysia 
national healthcare budgets. According to IDF 2019, the global annual diabetes 
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treatment cost constituted USD 700 billion, which was equivalent to the 10% of 
global health expenditure. The cost is expected to increase to USD 845 billion by 
year 2045 (IDF, 2019). In Malaysia, the annual expenditure for diabetes treatment 
was reported to be USD 3.6 billion in year 2019 and the cost is expected to increase 
to USD 5 billion by year 2045 (IDF, 2019). The economic burden brought by this 
pendemic disease could undermine the development advancement of the nation 
worldwide. 
According to the World Health Organization 2019, it was reported that 
diabetes mellitus is ninth in the world top ten leading cause of death (WHO, 2019). 
In addition, IDF 2019 also indicated that diabetes mellitus constituted 11.3% of 
global all-cause mortality, causing 4.2 million deaths globally in year 2019 (IDF, 
2019). Cardiovascular diseases were reported to be the main contributor to the 
mobidity and mortality in diabetic patients (Leon and Maddox, 2015); cardiovascular 
diseases account for an overwhelming 65-75% of deaths in people with diabetes (Ali 
et al., 2010). Prolonged hyperglycemia in diabetic individuals caused a significant 
risk of secondary cardiovascular complications. Therefore, the prevention of these 
diabetes-related cardiovascular complications, occurring at the macro- and 
microcirculation, will be effective means in the management of diabetes mellitus 
(Bate and Jerums, 2003). 
Type 2 diabetes mellitus (T2DM) is associated with a marked increase in the 
risk of atherosclerotic vascular disorders, including coronary, cerebrovascular, and 
peripheral artery diseases (Yamagishi, 2011). Atherosclerosis is characterized by 
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endothelial dysfunction (ED), vascular oxidative stress and inflammation and the 
build-up of lipid, cholesterol, calcium and cellular debris within the intima of the 
vessel wall; all these factors are implicated in plaque formation and vascular 
remodelling (Kampoli et al., 2009; Tibaut et al., 2019). Abnormal lipid metabolism, 
ED, vascular oxidative stress, inflammation, and vascular structural changes are 
factors that contribute to initiate and accelerate atherosclerosis, thus changes in these 
parameters can be used as markers for vascular damage in diabetes (Kampoli et al., 
2009: Niki, 2018; Steven et al., 2019; Ruparelia and Choudhury, 2020). In this study, 
these atherogenic markers were determined in a T2DM rat model induced by high-fat 
diet and low-dose streptozotocin.  
The endothelium consists of a monolayer of cells that run through the inner 
lining of the blood vessels. It regulates vascular tone and maintains vascular 
homeostasis. This layer can be disturbed resulting in its dysfunction termed 
endothelial dysfunction (ED). ED refers to diminished availability of endothelium-
derived relaxing factor (EDRF) or nitric oxide (NO), and increased production of 
vasoconstrictors (Tabit et al., 2010). ED occurs early before morphological changes 
become visible in the blood vessel wall. NO is formed in the endothelial cells via the 
enzymatic action of endothelial nitric oxide synthase (eNOS). ED plays a pivotal role 
in the pathogenesis of atherosclerosis in diabetes mellitus, and other cardiovascular 
diseases.  
Chronic hyperglycemia in diabetes mellitus is associated with long-term 
micro- and macro-vascular complications, which contributes to organ dysfunction 
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and failure, especially to the eyes, kidneys, nerves, heart, and blood vessels 
(Panigrahi et al., 2016). In the diabetes state, exposure of arterial tissue to high 
glucose concentration induces superoxide production and increased oxidative stress. 
Superoxide anion reacts with NO to form peroxynitrite, which eliminates the 
biological activity of NO (Sharma et al., 2012a). Superoxide anion alters the 
catalytic activity of eNOS in endothelial cells, thus impairing NO production. 
Reduction in NO production leads to ED.  
It has been observed that disorders induced by high-fat diet feeding resemble 
the human metabolic syndrome closely, with implications for cardiovascular health. 
Obesity and dyslipidemia are the components of metabolic syndrome, that are 
commonly seen in T2DM. High-fat diet intake causes obesity, which leads to insulin 
resistance. Insulin resistance and hyperglycemia increases diabetic complications 
such as atherosclerosis. High fat diet also leads to hyperlipidemia. Hyperlipidemia 
increases reactive oxygen species (ROS) production, resulting in oxidation and 
peroxidation of lipids, protein, and lipoprotein (Abbasnezhad et al., 2019). Low-
density lipoprotein cholesterol (LDL-C) and it’s oxidized form (oxLDL-C) play a 
major role in ED and atherogenesis. Oxidized LDL-C affects eNOS protein 
expression by increasing the synthesis of caveolin-1 (Davignon and Ganz, 2004), 
thus reducing NO production resulting in impairment of NO-mediated vasodilatory 
response (Blair et al., 1999; Wang et al., 2011).  
Inflammatory markers are associated with risk factors for the development of 
T2DM and macrovascular complications. Inflammation is a contributor to ED and 
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plays a pivotal role in the development of atherosclerosis. Inflammation can modify 
the synthesis and degradation of vasodilators and vasoconstrictors. At the intima 
layer of an arterial cell wall, monocytes release a number of inflammatory cytokines 
such as interleukins-1 (IL-1), IL-1b, IL-6, and tumor necrosis factor-alpha (TNF- α); 
all of which contribute to vascular endothelium injury and induce vascular wall 
plaque formation (Sun et al., 2018). TNF-α activates NADPH oxidase resulting in 
increased superoxide production, leading to a reduction in NO bioavailability (Picchi 
et al., 2006). TNF-α also reduces the expression of eNOS via augmented superoxide 
generation and affecting the half-life of eNOS mRNA, thus further reducing NO 
bioavailability (Zhang et al., 2002; Bitar et al., 2005).  NO protects blood vessels 
from endogenous injury by mediating molecular signals that inhibit leukocyte and 
platelet interaction with the vascular wall and prevent vascular smooth muscle cells 
(VSMC) proliferation and migration (Kubes et al., 1991; Sarkar et al., 1996). A 
reduction in endothelium-derived NO increases the activity of the pro-inflammatory 
transcription factor-like nuclear factor-kappa B (NF-kB), resulting in over-
expression of leukocyte adhesion molecules and an increase in the production of 
inflammatory cytokines particularly TNF-a. These activities promote VSMC and 
monocyte migration into the intima and the formation of foam cells, characterizing 
the initial morphological changes of atherosclerosis (Creager et al., 2003).  
Clinacanthus nutans (C. nutans) (Burm. f.) Lindau, commonly called Sabah 
Snake Grass, or “Belalai Gajah” in layman’s terms, is widely used in Malaysia, 
Thailand, and Indonesia as traditional medicine. C. nutans extracts have been 
reported to have the following properties: antioxidant, hypoglycemic, hypolipidemic, 
	 6 
and anti-inflammatory. A previous study had demonstrated high radical scavenging 
activity of C. nutans extracts in high fat and high cholesterol fed rat model treated 
with C. nutans (Sarega et al., 2016). Two in vitro studies have shown that C. nutans 
extract inhibits a-glucosidase activity (Wong et al., 2014; Alam et al., 2017). a-
glucosides ezyme is located at mucosal brush border of the small intestine; it 
functions to increase carbohydrate metabolism by increasing polysaccharide 
cleavage to glucose (Assefa et al., 2020). Thus, inhibition of this enzyme reduces 
carbohydrate metabolism, reducing glucose absorption into the blood from the small 
intestine, thus reducing blood glucose levels. Observation from these in vitro studies 
has been supported by a recent study in type 2 diabetes (T2DM) rat model treated 
with C. nutans extract (Umar Imam et al., 2019).  
C. nutans has also been reported to have hypolipidemic property as 
demonstrated in two previous studies (Sarega et al., 2016; Umar Imam et al., 2019). 
Both these studies demonstrated low serum total cholesterol (TC), triglycerides (TG), 
and LDL-C levels in hyperlipidemic (Sarega et al., 2016) and T2DM rats (Umar 
Imam et al., 2019) treated with C. nutans. In terms of inflammation, an in vitro study 
has reported that C. nutans reduced inflammatory cytokines, which include TNF-a, 
IL-1b and IL-6 in murine macrophages RAW 264.7 cells (Mai et al., 2016).  
 
1.2. Study Rationale 
Currently, there are five major classes of therapeutic drugs that are used to 
treat diabetes mellitus: thiazolidinediones, sulfonylureas, biguanides, meglitinide, 
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and alpha-glucosidase inhibitors. Despite their effectiveness, most of them cause 
certain unwanted side effects and potential adverse effects. Thiazolidinediones have 
been reported previously to cause weight gain, fluid retention, and heart failure 
(Juurlink et al., 2009). A study by Nissen and Wolski (2007) has shown that 
treatment with thiazolidinediones, particularly rosiglitazone increased the risk of 
myocardial infarction in diabetic patients (Nissen and Wolski, 2007). Sulfonylureas 
may cause hypoglycemia, increase body weight, gastrointestinal disturbances, and 
headache (Schier et al., 2001). Biguanides, particularly metformin, could cause 
abdominal pain, diarrhea, nausea, and lactic acidosis to diabetic patients (Nzerue et 
al., 2003). Although there are many anti-diabetic drugs available, the number of 
T2DM patients are still increasing, many of them not properly controlled. This may 
be due to anti-diabetic drug adverse effects and perhaps the limitation of action of 
each drug. Furthermore, despite taking these drugs, vascular complications of 
diabetes such as atherosclerosis and subsequent cardiovascular events such as 
coronary artery and cerebrovascular events are still highly prevalent in diabetic 
patients.  
Certain medicinal plants and natural products may have hypoglycemic effect 
with fewer side effects, easier to source locally, and at lower cost compared to 
current conventional drugs. They may be further investigated and developed as 
drugs, or used as adjunct to current drugs. It is possible that some of these natural 
products may be able to reduce diabetic vascular complications. Previous studies on 
C. nutans have shown that the leaves of this plant comprised of antioxidant, 
hypoglycemic, hypolipidemic, and anti-inflammatory effects. The antioxidant and 
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hypoglycemic effects of C. nutans might reduce the production of reactive oxygen 
species (ROS) particularly superoxide anion. Reduced superoxide anion ameliorates 
NO bioavailability in the endothelium, thus attenuate ED in diabetes. Besides that, 
the hypolipidemic property of C. nutans can reduce lipid levels in diabetes mellitus, 
particularly LDL-C, which may reduce LDL-C accumulation in the vascular wall. In 
addition, the anti-inflammatory property of C. nutans can reduce inflammatory 
cytokines production, particularly TNF-a. Reduced LDL-C and TNF-a levels 
attenuate the formation of foam cells and atherosclerotic plaque. Thus, these 
pharmacological properties of C. nutans have the potential to delay or prevent 
atherosclerosis in diabetes mellitus.  
To date, there are no studies on the effects of C. nutans on vascular ED (an 
early precursor to atherosclerosis), vascular oxidative stress and inflammation status 
in T2DM. Thus, the present study aimed to determine the effects of methanolic 
leaves extract of C. nutans on these atherogenic risk markers in high-fat diet and 
low-dose streptozotocin (STZ)-induced T2DM animal model. 
 
1.3 Hypothesis of the Study 
1. T2DM rats induced by high-fat diet and low-dose STZ showed increased 
atherogenic risk. 
2. Methanolic extract of Clinacanthus nutans (CNME) attenuates atherogenic risk 
markers in T2DM rats. 
	 9 
1.4 Objectives of the Study 
1.4.1 General Objective 
To determine the atherogenic risk of T2DM rats induced by high-fat diet and low-
dose STZ, and investigate the effects of treatment with the methanolic extract of 
Clinacanthus nutans (CNME) leaves on atherogenic risk markers in T2DM rats.  
 
1.4.2 Specific Objectives 
1. To determine endothelium-dependent and -independent relaxation and 
contraction in the aorta of non-diabetic and T2DM rats, and evaluate the effects 
of CNME treatment on these parameters. 
2. To determine the expression of eNOS protein in the aorta of non-diabetic and 
T2DM rats, and evaluate the effect of CNME treatment on eNOS protein 
expression. 
3. To assess oxidative stress markers in the aorta of non-diabetic and T2DM rats by 
measuring SOD activity and MDA level, and evaluate the effects of CNME 
treatment on these markers. 
4. To determine the level of inflammation (by measuring tumor necrosis factor-
alpha, TNF-a) in the aorta of non-diabetic and T2DM rats, and evaluate the 
effect of CNME treatment on this marker. 
5. To assess early vascular structural changes (intima-media thickness and presence 
of foam cells) in the aorta of non-diabetic and T2DM rats, and evaluate the 







2.1.1 Structure and Function of Blood Vessel Wall 
The blood vessel contributes to homeostasis by providing blood flow to and 
from the heart to organs and tissues, allowing for the exchange of nutrients and waste 
in tissues. They also play an important role in adjusting the velocity and volume of 
blood flow. There are three main types of blood vessels, which include arteries, 
capillaries and veins. Although blood vessel may vary in size, their general structure 
remains similar except at the level of the capillaries. Starting from the external 
surface, the blood vessel wall consists of the tunica adventitia, which is mainly made 
up of collagen and connective tissues (Figure 2.1). The vasa vasorum form a network 
of microvessels that lie in the adventitia. The middle layer is tunica media with the 
vascular smooth muscle cells (VSMC) and finally the tunica intima with the 
endothelium that surrounds the lumen where the blood flows. The endothelium is a 
thin layer of flattened cells that lines the inner surface of the entire cardiovascular 
system (Tortora and Derrickson, 2009).  
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The endothelium is a monolayer of endothelial cells that lines the interior 
surface of blood vessels and cardiac valves in the entire vascular system. This organ 
(endothelium) contains approximately 1 ´ 1013 cells and almost one-kilogram of 
weight. The shape of endothelial cells varies across the vascular tree, but they are 
generally thin and slightly elongated, with each endothelial cell being roughly 50-70 
µm long, 10-30 µm wide and 0.1-10 um thick. Endothelial cells are metabolically 
active with important endocrine, paracrine, and autocrine functions. These functions 
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are indispensable for the maintenance of vascular homeostasis under physiological 
conditions (Bonetti et al., 2003; Sena et al., 2013).  
The functions of vascular endothelium include vascular growth and 
remodeling, regulation of vessel integrity, metabolism, cell adhesion, angiogenesis, 
vascular permeability, tissue growth, homeostasis and immune responses. In 
addition, the vascular endothelium plays a major role in the regulation of vascular 
tone, maintaining blood fluidity, inflammatory responses and controlling tissue blood 
flow (Félétou et al., 2011; Sena et al., 2013). As a main regulator of vascular 
homeostasis, the endothelium maintains the balance between vasodilation and 
vasoconstriction, inhibition and promotion of the migration and proliferation of 
smooth muscle cells, fibrinolysis and thrombogenesis (Félétou et al., 2011; Sena et 
al., 2013). Endothelial cells produced endothelium-derived relaxing factors (EDRF) 
and endothelium-derived contracting factors (EDCF) to regulate vasodilation and 
vasoconstriction respectively. Generally, EDRF consist of nitric oxide, prostacyclin 
and endothelium-derived hyperpolarizing factor. EDCF comprise of thromboxane 
A2, endothelin-1 and angiotension II. Any disturbance in this tightly regulated 
equilibrium of vasodilation and vasoconstriction leads to endothelial dysfunction 
(ED).  
 
2.1.3 Nitric Oxide 
Nitric oxide (NO) is a structurally simple molecule that exerts effects on a 
wide variety of actions in the vasculature. NO is an endothelium-derived relaxing 
factor (EDRF) that was discovered in 1980 by Furchgott and Zawadzki (Furchgott 
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and Zawadzki, 1980); it has been recognized as a key determinant of vascular 
homeostasis, regulating several physiological properties of blood vessel, including 
vascular permeability, vasodilation and anti-thrombotic properties (Jin and Loscalzo, 
2010). The bioavailability of NO represents a central feature of the normal vascular 
function and is required for maintaining vasodilator tone and inhibiting platelet 
activation, thereby preventing thrombosis and its clinical vascular consequences. 
Decreased production or increased metabolism of NO lead to NO insufficiency 
within the vasculature and its pathological consequences (Jin and Loscalzo, 2010). 
 
2.1.3 (a) Synthesis of NO 
NO synthesis occurs in a range of cell types within the vasculature, which 
include macrophages and the vascular endothelium (Jin and Loscalzo, 2010). NO is 
synthesized by a class of enzymes known as nitric oxide synthase (NOS), which 
include endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS 
(iNOS). The three NOS isoforms are characterized by their site of synthesis, pattern 
of expression, and calcium (Ca2+) tendency: NOS I or nNOS is expressed primarily 
in neurons; NOS II or iNOS, is expressed in macrophages, neutrophils, platelets and 
VSMC, as wells as in other nonvascular cells; NOS III or eNOS is constitutively 
expressed in endothelial cells. nNOS and eNOS are more critical for normal 
physiology, whereas iNOS is associated with injury and inflammation (Kaszkin et 
al., 2004). 
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All of the enzymes catalyzed the five-electron oxidation of one of the 
terminal guanidine nitrogen atom of L-arginine to produce L-citruline and NO. 
Enzyme activity requires flavin mononucleotide (FMN), flavin adeninine 
dinucleotide (FAD), tetrahydrobiopterin (BH4), Ca2+-calmodulin, and heme, which 
serve as cofactors, along with nicotinamide adenine dinucleotide phosphate 
(NADPH) and molecular oxygen, which serve as co-substrates (Jin and Loscalzo, 
2010) (Figure 2.2).  
 
 
Figure 2.2 The synthesis of the nitric oxide. Figure modified from Jin and 
Loscalzo, (2010).   
 
2.1.3 (b) Pathways of NO 
Once synthesized, NO diffuses across the endothelial cell membrane and 
enters the VSMC where it stimulates soluble guanylyl cyclase (sGC) to induce 
formation of cyclic guanosine monophosphate (cGMP) from guanosine triphosphate 
(GTP). cGMP activates protein kinase G (PKG) which prevent Ca2+ influx from 
voltage-dependent Ca2+ channel (VDCC) and Ca2+ release mediated by inositol 1,4,5-
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triphosphate receptor (IP3R). PKG also act as sarco/endoplasmic reticulum calcium 
ATPase (SERCA) to promote the reuptake of cytosolic Ca2+ into the sarcoplasmic 
reticulum. It results in the reduction of intracellular Ca2+ concentration and 
inactivation of calmodulin, which is no longer able to activate myosin light chain 
kinase (MLCK). The depletion of intracellular Ca2+ also increases the activity of 
myosin light chain phosphatase (MLCP). The actin-myosin cross-bridge is broken 








Figure 2.3 Schematic diagram of possible mechanism of NO-mediated response 
in the blood vessel. The activation of endothelial cells by ACh or shear 
stress leads to an increase in intracellular Ca2+ concentration and NO is 
produced. NO diffuse into VSMC and activates sGC, leading to 
production of cGMP. cGMP activates PKG. NO can also directly 
stimulate SERCA and facilitate the removal of Ca2+ from smooth 
muscle cytosol into the sarcoplasmic reticulum store. Figure modified 
from Zhao et al. (2015) (Zhao et al., 2015). 
 
ATP, adenosine triphosphates; CaM, calmodulin; M, muscarinic receptor; MLCK, 
myosin light chain phosphatase; PKG, protein kinase G; SERCA, sarco/endoplamic 





2.2 Diabetes Mellitus 
2.2.1 Definition and Classification 
Diabetes mellitus is group of metabolic disorders characterized by 
hyperglycemia resulting from defects in insulin secretion and/ or insulin action 
(American Diabetes Association, 2020). Diabetes can be classified into three 
categories depending on the underlying etiology.  
Type 1 diabetes mellitus (T1DM), previously known as insulin-dependent 
diabetes, results from autoimmune destruction of b-cells of the pancreas. In this form 
of diabetes, the rate of b-cells destruction is quite variable, being rapid in some 
individuals (mainly infants and children) and slow in others (mainly adults). Some 
patients, particularly children and adolescent, may present with ketoacidosis as the 
first manifestation of the disease. Others have modest fasting hyperglycemia that can 
rapidly change to severe hyperglycemia and /or ketoacidosis in the presence of 
infection or other stress. At this latter stage of the disease, there is little or no insulin 
secretion (American Diabetes Association, 2020).  
Type 2 diabetes mellitus (T2DM) is associated with a relative insulin 
deficiency rather than absolute (American Diabetes Association, 2020). Most 
patients with T2DM have some degree of insulin resistance associated with obesity 
as one of the major risk factors. Obesity is defined as excessive fat accumulation in 
adipose tissue that extends to morbidity and mortality due to weight-related 
complications; to the extent that health is impaired. Insulin resistance occurs due to 
reduced insulin sensitivity such that the cells are unable to respond well to insulin, 
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thus there is impairment in glucose uptake by cells, thus inability of cells to use 
glucose for energy. Hence, more insulin needs to be produced by the pancreatic b-
cells to compensate for insulin resistance. Progressively, the amount of insulin 
become deficient in meeting further cellular requirements, a condition known as 
relative insulin deficiency, predisposing to the onset of hyperglycemia. Chronic 
condition of hyperglycemia could further damage the pancreatic b-cell, resulting in 
absolute insulin deficiency (Pratley, 2013).  
Gestational diabetes mellitus is a metabolic disorder associated with glucose 
intolerance, which was first identified during pregnancy (American Diabetes 
Association, 2020). It occurs when placenta produce insulin-blocking hormones that 
leads to high blood glucose level. Women affected with gestational diabetes have a 
seven-fold increased risk of developing T2DM in the future after initial diagnosis. 
Their children are also prone to develop T2DM early in life (Bellamy et al., 2009; 
Rayanagoudar et al., 2016). 
 
2.2.2 Diagnosis, Symptoms and Medication 
T2DM is most commonly diagnosed using the parameters glycated 
haemoglobin (HbA1c) and fasting blood glucose (FBG). HbA1C indicates the average 
blood glucose levels for the past three months while FBG is the blood glucose level 
after an overnight fast. Individuals with HbA1C levels of 6.5% or higher and FBG 
levels of 7.0 mmol/L or more is diagnosed as having T2DM (American Diabetes 
Association, 2008). Symptoms of diabetes may include frequent urination, excessive 
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thirst, increase in appetite, unusual fatigue, sudden weight loss, nausea, dizziness and 
slow wound healing. 
Pharmacological management of T2DM may require the use of oral 
hypoglycemic agents, especially when a strict diet and exercise plan have failed to 
reduce blood glucose level. The oral hypoglycemic agents are classified into five 
major classes, which include biguanides, meglitinides, sulfonylureas, a-glucosidase 
inhibitors and thiazolidinediones (TZD). The biguanide class has metformin as a 
member, which improves insulin sensitivity and increase glucose uptake. 
Meglitinides include repaglinide and nateglinide; while sulfonylureas include 
gliclazide, glibenclamide and glimepiride. Both meglitinides and sulfonylureas 
promote the release of insulin from pancreatic b-cells. a-glucosidase inhibitors 
include acarbose and miglitol; they, preventing the digestion of carbohydrate in the 
intestine. TZD include pioglitazone and rosiglitazone; these drugs reduce insulin 
resistance and makes body tissue more sensitive to the effects of insulin insulin’s 
effects. Insulin therapy was considered if the situation of inadequate glycemic 
control on optimal dose and number of oral hypoglycemic agents (Ministry of Health 
Malaysia, 2015b). 
In this study, metformin has been used as a positive control in the treatment 
of T2DM rat model. Metformin is the often the first line of drug used in the 
management of T2DM (Kinaan et al., 2015). It is decreasing insulin resistance thus 
increases glucose uptake and use by target tissues. This also reduces hyperglycemia. 
Other reported mechanisms of action of metformin in reducing blood glucose levels 
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include: i) reduced hepatic and renal gluconeogenesis; ii) slowing of glucose 
absorption from gastrointestinal tract and improve peripheral glucose uptake and 
utilization; iii) reduction of plasma glucagon levels. 
 
2.2.3 Animal Models of Diabetes Mellitus 
Animal models have been used extensively to investigate in vivo efficacy, 
mode of action and side effects of anti-diabetic drugs and plants. Due to the 
heterogeneity of diabetic conditions in man, no single animal model is entirely 
representative of a particular type of human diabetes. Thus, many different animal 
models have been used, each displaying a different selection of features seen in 
human diabetic states (Eddouks et al., 2012). The most widely used animal models 
are small rodents, which are less expensive to maintain than larger animals and 
generally show a more rapid onset of their diabetic condition consistent with their 
short lifespan.  
Diabetes can be developed via surgical, pharmacologic, or genetic 
manipulations in several animal species. Streptozotocin (STZ) is the most frequently 
used drug to induce diabetes and this model has been useful for the study of multiple 
aspects of diabetes mellitus. STZ is often administered parentally via intraperitoneal, 
intravenous or subcutaneous routes (Eddouks et al., 2012). STZ enters the b-
pancreatic cell via a glucose transporter 2 (GLUT2) and causes alkylation of DNA 
(Ishizaka et al., 2010; Eddouks et al., 2012). As a result of the DNA alkylation, 
pancreatic b-cell is destroyed by necrosis. The destruction of pancreatic b-cells 
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disrupts the ability of the pancreas to produce insulin, leading to a T1DM animal 
model. 
A high-fat diet can be formulated by using a standard diet combined with 
animal fat (ghee) and sugar (to increase the caloric value). Feeding high-fat diet in 
developing a T2DM rat model has become increasingly popular in recent years. 
Feeding high-fat diet leads to the development of obesity and consequently insulin 
resistance. Subsequent administration of a low-dose STZ injection causes mild 
dysfunction in pancreatic b-cell without destroying all the pancreatic b-cells. This 
will compromise insulin secretion by the pancreas. Thus, feeding high-fat diet with 
administration of low-dose STZ closely mimics the natural development of T2DM 
(from insulin resistance to b-cell dysfunction) as well as its metabolic features (Guo 
et al., 2018). Studies have shown that mice fed with only high-fat diet develop 
symptoms related to T2DM such as hyperinsulinemia and insulin resistance but not 
hyperglycemia (Srinivasan et al., 2005; Magalhães et al., 2019). On the other hand, 
using a high-fat diet with a low-dose STZ has shown positive results in establishing 
obesity, insulin resistance, T2DM and hyperglycemia (Magalhães et al., 2019). 
However, currently there are no standardization on the development of T2DM 
animal model in terms of composition of the high-fat diet, dose of STZ to be 
administered, the species and the age of animals to be used (Atanasovska et al., 





2.3 Diabetes and Vascular Complications 
Cardiovascular complications are the primary cause of death in diabetic 
patients. Diabetes can cause microvascular and macrovascular complications. 
Microvascular complications include retinopathy (eye damage), neuropathy (neuron 
damage) and nephropathy (kidney damage). Macrovascular complications comprise 
of coronary artery disease, cerebrovascular disease and peripheral arterial disease 
(Forbes and Cooper, 2013). Diabetes affects the function of multiple cell types in the 
blood vessel, including the endothelium and VSMC. 
 
2.3.1 Effect of Diabetes on the Endothelium  
Diabetes is associated with endothelial dysfunction (ED). ED is an early step 
in the development of atherosclerosis. ED is characterized by impaired endothelium-
mediated relaxation. It occurs due to the imbalance between vasodilation and 
vasoconstriction due to reduction in the bioavailability of vasodilators, particularly 
NO (Zhu et al., 2011). In diabetes, hyperglycemia increases reactive oxygen species 
(ROS) production via glucose autoxidation and advanced glycation end products 
(AGEs). Increase ROS production augmented its tendency to react with NO to form 
cytotoxic oxidant peroxynitrite. Peroxynitrite lead to degradation of eNOS cofactor 
tetrahyrobiopterin (BH4), causing the uncoupling of eNOS, thus reducing NO 
bioavailability (Endemann and Schiffrin, 2004). In diabetes, ED leads to increased 
endothelial cell permeability, which increase LDL uptake into subendothelial space. 
LDL-C undergoes oxidation (oxLDL-C) due to increase ROS level; resulting from 
hyperglycemia in diabetes. oxLDL-C is taken up by macrophages and undergo 
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inflammatory process, thus lead to foam cell formation and subsequently 
atherosclerotic plaque. In addition, reduced NO bioavailability upregulated adhesion 
molecules such as intracellular adhesion molecule (ICAM), vascular adhesion 
molecule (VCAM) and E-selectin in endothelial cells via induction of nuclear factor 
kappa B (NF-kB) expression (Khan et al., 1996). Increases in adhesion molecules 
initiate the inflammatory process that lead to the atherosclerotic plaque formation.  
 
2.3.1 (a) Endothelium-dependent Relaxation 
Previous studies have shown that NO-mediated relaxations were reduced in 
the aorta of Goto Kakizaki (non-obese, spontaneous T2DM rat model) rats (Sena et 
al., 2011; Kobayashi et al., 2012) and high-fat diet fed with low-dose STZ-induced 
T2DM rats (Oztürk et al., 2015). It was shown that the impairment of ACh-induced 
endothelium-dependent relaxation was due to reduced bioavailability of NO, 
decreased expression of eNOS mRNA, and higher oxidative stress level in rat aorta 
of both diabetic rat models (Sena et al., 2011; Oztürk et al., 2015). In diabetes, 
hyperglycemia increases production free radical species particularly superoxide 
anion.  High production of superoxide anion affects the activity of NO; it reacts with 
NO to form peroxynitrite, which reduced NO bioavailability resulting in the 
impairment of NO-mediated relaxation. 
 
2.3.1 (b) Endothelium-dependent Contraction 
A previous study by Tesfamariam et al. (1989) has shown that ACh-induced 
endothelium-dependent contraction was increased in aortic rings of diabetic rabbits 
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(Tesfamariam et al., 1989). Another study by Shi et al. (2007) reported that calcium 
ionophore-induced endothelium-dependent contraction was increased in the aorta of 
T1DM diabetic rats (Shi et al., 2007). It has been shown that the hypercontractility in 
T1DM diabetic arteries were associated with high oxidative stress level which 
increases the production of endothelium-derived contracting factors (EDCF) (Tang et 
al., 2007; Matsumoto et al., 2008;). Due to hyperglycemia, increased production of 
superoxide anion reduces the activity of the antioxidant enzyme SOD to counteract 
the superoxide anion, thus reducing NO bioavailability. Reduced NO leads to EDCF 
activation and production, thus resulting in augmented smooth muscle contraction.  
 
2.3.2 Effect of Diabetes on Vascular Smooth Muscle 
2.3.2 (a) Vascular Smooth Muscle Relaxation 
Studies have shown that the response of VSMC to the NO donor, sodium 
nitroprusside was not affected in renal arteries and aorta of T2DM rats (Viswanad et 
al., 2006; Sena et al., 2011). However, a previous study has shown that sodium 
nitropruside-induced relaxation was attenuated in female pregnant T2DM rat model 
(Goulopoulou et al., 2014).  
 
2.3.2 (b) Vascular Smooth Muscle Contraction 
Vascular smooth muscle response to the endothelium-independent 
vasoconstrictor, phenylephrine was shown to be increased in small mesenteric and 
aorta of 12 weeks old T2DM db/db mice (Guo et al., 2005) and thoracic aorta of 24 
weeks old T2DM ob/ob mice (Nevelsteen et al., 2013). It has been shown that 
